Venus Remedies Intrinsic Value
VENUSREM Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1325.28 | ₹1060.22 - ₹1590.34 | +91.7% | EPS: ₹60.24, Sector P/E: 22x |
| Book Value Method | asset | ₹863.08 | ₹776.77 - ₹949.39 | +24.9% | Book Value/Share: ₹431.54, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1200.00 | ₹1080.00 - ₹1320.00 | +73.6% | Revenue/Share: ₹600.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1012.46 | ₹911.21 - ₹1113.71 | +46.5% | EBITDA: ₹132.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹614.16 | ₹491.33 - ₹736.99 | -11.1% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹385.54 | ₹346.99 - ₹424.09 | -44.2% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹930.71 | ₹837.64 - ₹1023.78 | +34.7% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹738.46 | ₹664.61 - ₹812.31 | +6.8% | ROE: 14.3%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹764.79 | ₹688.31 - ₹841.27 | +10.7% | EPS: ₹60.24, BVPS: ₹431.54 |
Want to compare with current market value? Check VENUSREM share price latest .
Valuation Comparison Chart
VENUSREM Intrinsic Value Analysis
What is the intrinsic value of VENUSREM?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Venus Remedies (VENUSREM) is ₹863.08 (median value). With the current market price of ₹691.15, this represents a +24.9% variance from our estimated fair value.
The valuation range spans from ₹385.54 to ₹1325.28, indicating ₹385.54 - ₹1325.28.
Is VENUSREM undervalued or overvalued?
Based on our multi-method analysis, Venus Remedies (VENUSREM) appears to be trading below calculated value by approximately 24.9%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 23.79 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.28 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 14.3% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 16.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.09x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Venus Remedies
Additional stock information and data for VENUSREM
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹86 Cr | ₹48 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹37 Cr | ₹33 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹37 Cr | ₹8 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹41 Cr | ₹33 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹132 Cr | ₹132 Cr | Positive Free Cash Flow | 8/10 |